LLY

Eli Lilly and Company

Halal Rating :
Comfortable
Last Price $767.95 Last updated:
Market Cap $719.79b
7D Change -2.68%
1 Year Change 34.26%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Pharmaceutical Preparations
Exchange NYSE
Next Earnings Date Oct. 30, 2024

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $11.44b $9.91b - - 0.00% 0.00%
June 30, 2024 $11.3b $7.59b - - 0.00% 0.00%
March 31, 2024 $8.77b $6.26b - - 0.00% 0.00%

Company Impact

Help us evaluate Eli Lilly and Company's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates